NanoVibronix Adjourns Special Meeting of Stockholders
December 21 2021 - 10:30AM
NanoVibronix, Inc. (the “Company”) (NASDAQ: NAOV) announced today
that the Company’s Special Meeting of Stockholders, scheduled for
10:00 a.m. Eastern time today, December 21, 2021, has been
adjourned to allow for more time for stockholders to vote due to a
lack of quorum. The meeting has been scheduled to reconvene on
December 29, 2021 at 10:00 a.m. Eastern time and will be held
virtually online at www.virtualshareholdermeeting.com/NAOV2021SM2.
During the period of the adjournment, the Company will continue
to solicit proxies from its stockholders with respect to the
proposal set forth in the Company’s proxy statement. Proxies
previously submitted in respect to the Special Meeting will be
voted at the reconvened meeting unless properly revoked.
The Company encourages all stockholders who have not yet voted
to do so before December 28, 2021 at 11.59 p.m. Eastern time. The
stockholders may vote by internet at www.proxyvote.com, or by
telephone at 1-800-690-6903 for stockholders of record and
1-800-454-8683 for beneficial stockholders, or by returning a
properly executed proxy card to Vote Processing, c/o Broadridge, 51
Mercedes Way, Edgewood, NY 11717.
If you have any questions, need additional material, or need
assistance in voting your shares, please feel free to contact the
firm assisting the Company in the solicitation of proxies,
Kingsdale Advisors. Brokers, banks and other nominees may call
416-867-2272. Stockholders may call toll-free 1-877-657-5856. Or
you may contact Kingsdale Advisors by email at
contactus@kingsdaleadvisors.com.
About NanoVibronix
NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company
focusing on noninvasive biological response-activating devices that
target wound healing and pain therapy and can be administered at
home, without the assistance of medical professionals. Our
WoundShield, PainShield and UroShield products are backed by novel
technology which relates to ultrasound delivery through surface
acoustic waves. Additional information about the Company is
available at: www.nanovibronix.com.
Additional Information and where to find it
The Company has filed a definitive proxy statement and
associated proxy card with the U.S. Securities and Exchange
Commission (the “SEC”) in connection with the solicitation of
proxies for the Special Meeting of Stockholders of the Company (the
“Special Meeting”) on December 21, 2021. The Company, its
directors, its executive officers and certain other individuals set
forth in the definitive proxy statement will be deemed participants
in the solicitation of proxies from shareholders in respect of the
Special Meeting. Information regarding the names of the Company’s
directors and executive officers and certain other individuals and
their respective interests in the Company by security holdings or
otherwise are set forth in the definitive proxy statement filed
with the SEC on November 16, 2021. BEFORE MAKING ANY VOTING
DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL
RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING
THE DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO AND THE
ACCOMPANYING PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. Investors and shareholders can obtain a copy of the
documents filed by the Company with the SEC, including the
definitive proxy statement, free of charge by visiting the SEC’s
website, www.sec.gov. The Company’s stockholders can also obtain,
without charge, a copy of the definitive proxy statement and other
relevant filed documents when available from the Company’s website
at https://ir.nanovibronix.com/sec-filings.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) the geographic, social and
economic impact of COVID-19 on the Company’s ability to conduct its
business and raise capital in the future when needed, (ii) market
acceptance of our existing and new products or lengthy product
delays in key markets; (iii) negative or unreliable clinical trial
results; (iv) inability to secure regulatory approvals for the sale
of our products; (v) intense competition in the medical device
industry from much larger, multinational companies; (vi) product
liability claims; (vii) product malfunctions; (viii) our limited
manufacturing capabilities and reliance on subcontractor
assistance; (ix) insufficient or inadequate reimbursements by
governmental and/or other third party payers for our products; (x)
our ability to successfully obtain and maintain intellectual
property protection covering our products; (xi) legislative or
regulatory reform impacting the healthcare system in the U.S. or in
foreign jurisdictions; (xii) our reliance on single suppliers for
certain product components, (xiii) the need to raise additional
capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be
costly, dilutive or difficult to obtain; (xiv) our conducting
business in foreign jurisdictions exposing us to additional
challenges, such as foreign currency exchange rate fluctuations,
logistical and communications challenges, the burden and cost of
compliance with foreign laws, and political and/or economic
instabilities in specific jurisdictions; and (xv) market and other
conditions. More detailed information about the Company and the
risk factors that may affect the realization of forward looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise, except as required by law.
Brett Maas, Managing Principal
Hayden IR, LLC
646-536-7331
brett@haydenir.com
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Sep 2024 to Oct 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Oct 2023 to Oct 2024